Galderma has secured FDA approval for Restylane Contour for temple hollowing, a structural filler indication that targets age-related volume loss in the temporal region. This approval expands Restylane's footprint in the premium contouring space, where practitioners command higher per-syringe fees for anatomically precise, three-dimensional work.
Injectables
Galderma Wins FDA Approval for Restylane Contour — Temple Indication Expands Structural Filler Segment
New indication for temple volume restoration adds a high-skill, high-margin treatment to Restylane's portfolio.
Temple treatment is a high-skill procedure that justifies premium pricing and attracts experienced injectors.
Temple treatment is a high-skill procedure—improper placement risks vascular compromise and blindness—which means it attracts experienced injectors and justifies premium pricing. Restylane Contour's approval gives you a branded, cleared option for a procedure many practices currently perform off-label with other HA fillers. The indication also sits within Galderma's loyalty and rebate infrastructure, likely tied to Restylane's broader bundling strategy. For practices already deep in Restylane, this is an easy add; for those weighted toward AbbVie, it's a competitive pressure point that may shift your per-unit acquisition cost.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.